Lentivirus is challenging to manufacture. Unwanted transgene expression and viral genome instability are two common and critical issues.
Lentitek can help you solve these challenges through a combination of expert design services and the incorporation of our unique manufacturing technology, which effectively eliminates unwanted transgene expression by stabilising the vector genome during the manufacturing process.
Our approach enables you to optimise vector performance, enhance quality and safety, and minimise potentially hazardous off-target effects.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Edinburgh, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.lentitek.com
- HQ
- Edinburgh
Lentitek Questions
Lentitek's website is http://www.lentitek.com
Lentitek's LinkedIn profile is https://uk.linkedin.com/company/lentitek
Lentitek has
9 employees.
View email and phone details for 9
employees at Lentitek.
Lentitek's industry is
Biotechnology Research
Lentitek's top competitors are
Biocomposites,
Medannex Ltd,
Akari Therapeutics, Plc,
Osivax,
Rentschler Biopharma,
Resolution Therapeutics,
Zelluna,
Exogene,
Revolver Therapeutics,
Epoch Biodesign.
Lentitek's categories are Biotechnology Research
Lentitek's founding year is 2019
